Literature DB >> 8490895

Treatment compliance in childhood and adolescence.

C K Tebbi1.   

Abstract

Experience reveals that there is significant noncompliance with self-administered medication, especially in chronic conditions such as cancer. Noncompliance transcends the boundary of disease categories and age group. However, this is most prevalent during the adolescent years when the process of transition from parental dependency to autonomy produces confusion as to who is responsible for administration of medication. Noncompliance can result in the misjudgment of efficacy of a drug or regimen that may necessitate additional tests, alteration of dose, treatment course, and hospitalization. Currently in the United States, a large percentage of pediatric cancer patients are treated according to research protocols. In a research setting, noncompliance can result in erroneous or inconsistent findings, potentially affecting investigational results. With the availability of venous access ports and sophisticated, yet easy-to-operate pumps, increasingly, it is possible to administer parenteral medications at home. This adds a new dimension to the self-administration of medication that previously concerned mainly oral therapy. Various factors concerning the patient, disease, health providers, and treatment characteristics determine how well a given regimen is adhered to. Because a significant number of determinants are involved, it is often not possible, with any degree of certainty, to identify noncompliers or to predict the level of patient adherence to the treatment. Major factors in any successful therapy include the availability of effective medications and compliance with therapy regimen. With the advent of more successful treatments for childhood and adolescent cancer, the compliance factor is gaining greater importance because therapy currently is given with curative, rather than palliative intent. The availability of questionnaires, tests, and devices can help, to some extent, examine the degree of patient compliance. Family and social support, individualized programs, reminders to reduce forgetfulness, personalized needs assessment, and education can reduce noncompliance. Compliance is a complex and multifaceted issue that is still poorly understood and requires further investigation.

Entities:  

Mesh:

Year:  1993        PMID: 8490895     DOI: 10.1002/1097-0142(19930515)71:10+<3441::aid-cncr2820711751>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Clinical trials in youth with type 2 diabetes.

Authors:  Julie Anne L Gemmill; Rebecca J Brown; Radha Nandagopal; Luisa M Rodriguez; Kristina I Rother
Journal:  Pediatr Diabetes       Date:  2011-02       Impact factor: 4.866

2.  Medical and psychosocial associates of nonadherence in adolescents with cancer.

Authors:  Stephanie E Hullmann; Lauren D Brumley; Lisa A Schwartz
Journal:  J Pediatr Oncol Nurs       Date:  2014-11-03       Impact factor: 1.636

3.  "Juvenile" oncology--a missing subspecialty. The experience of a reference cancer centre.

Authors:  George Pentheroudakis; Davide Mauri; Lida Kostadima; Vassilis Golfinopoulos; George Alexiou; Anestis Karakatsanis; Nicholas Pavlidis
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

4.  Non-compliance with oral chemotherapy in childhood leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  BMJ       Date:  1996-11-16

5.  Feasibility and Acceptability of Maternal Choline Supplementation in Heavy Drinking Pregnant Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Sandra W Jacobson; R Colin Carter; Christopher D Molteno; Ernesta M Meintjes; Marjanne S Senekal; Nadine M Lindinger; Neil C Dodge; Steven H Zeisel; Christopher P Duggan; Joseph L Jacobson
Journal:  Alcohol Clin Exp Res       Date:  2018-06-13       Impact factor: 3.455

Review 6.  Drug compliance in adolescents: assessing and managing modifiable risk factors.

Authors:  Betty Staples; Terrill Bravender
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  Anemia in pediatric dialysis patients in end-stage renal disease network 5.

Authors:  Jeffrey J Fadrowski; Susan L Furth; Barbara A Fivush
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

8.  Social support, flexible resources, and health care navigation.

Authors:  Elizabeth A Gage-Bouchard
Journal:  Soc Sci Med       Date:  2017-08-18       Impact factor: 4.634

9.  How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic.

Authors:  Justine M Kahn; Uma H Athale; Luis A Clavell; Peter D Cole; Jean-Marie Leclerc; Caroline Laverdiere; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Stephen E Sallan; Lewis B Silverman; Kara M Kelly
Journal:  J Pediatr Health Care       Date:  2016-07-25       Impact factor: 1.812

10.  Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.

Authors:  L Bellamy; N Rosencher; Bi Eriksson
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.